About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Called the photovoltaic retina implant microarray (PRIMA), the small system uses a subretinal ... The researchers said they ...

Michael O'Connell, Chief Analytics Officer at Spotfire, on his journey to technology leadership in energy management ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...